1. Retracted: MiR-181a Promotes Apoptosis and Reduces Cisplatin Resistance by Inhibiting Osteopontin in Cervical Cancer Cells
   Xiaofei Xu et al, 2019, Cancer Biotherapy and Radiopharmaceuticals CrossRef
2. Osteopontin in Cancer: Mechanisms and Therapeutic Targets
   Yoshinobu Kariya et al, 2022, International Journal of Translational Medicine CrossRef
3. Osteopontin: A Key Multifaceted Regulator in Tumor Progression and Immunomodulation
   Venketesh K. Panda et al, 2024, Biomedicines CrossRef
4. Osteopontin and Cancer: Insights into Its Role in Drug Resistance
   Chengcheng Hao et al, 2023, Biomedicines CrossRef
5. Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines
   Yuki Haga et al, 2017, PLOS ONE CrossRef
6. Prognostic and predictive significance of osteopontin in malignant neoplasms
   E. Yu. Zubareva et al, 2021, Advances in Molecular Oncology CrossRef
7. Biomarkers and Genetic Markers of Hepatocellular Carcinoma and Cholangiocarcinoma—What Do We Already Know
   Jacek Baj et al, 2022, Cancers CrossRef
8. Reinforcing osteopontin as a marker of central nervous system relapse in paediatric B‐cell acute lymphoblastic leukaemia: SPP1 splice variant 3 in the spotlight
   Júlio C. Santoro et al, 2019, British Journal of Haematology CrossRef
9. SPP1 expression indicates outcome of immunotherapy plus tyrosine kinase inhibition in advanced renal cell carcinoma
   Xianglai Xu et al, 2024, Human Vaccines & Immunotherapeutics CrossRef
10. The Effects of Qinghao-Kushen and Its Active Compounds on the Biological Characteristics of Liver Cancer Cells
    Jingmin Ji et al, 2022, Evidence-Based Complementary and Alternative Medicine CrossRef
11. circMRPS35 promotes malignant progression and cisplatin resistance in hepatocellular carcinoma
    Peng Li et al, 2022, Molecular Therapy CrossRef
12. Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies
    Sayed Shahabuddin Hoseini et al, 2017, Cancer Letters CrossRef
13. Osteopontin Expression Is Associated with the Poor Prognosis in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy
    Tai-Jan Chiu et al, 2018, BioMed Research International CrossRef
14. Resveratrol enhances the antiliver cancer effect of cisplatin by targeting the cell membrane protein PLA2
    Yu Gao et al, 2024, Frontiers in Oncology CrossRef
15. Accounting for tumor heterogeneity when using CRISPR-Cas9 for cancer progression and drug sensitivity studies
    Jessica F. Olive et al, 2018, PLOS ONE CrossRef
16. EMT and Inflammation: Crossroads in HCC
    Burcu Sengez et al, 2023, Journal of Gastrointestinal Cancer CrossRef
17. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway
    Xin Yin et al, 2017, Journal of Experimental & Clinical Cancer Research CrossRef
18. CCDC167 promotes hepatocellular carcinoma cell proliferation and is associated with the immune microenvironment of hepatocellular carcinoma
    Qianwen Wang et al, 2024, Arabian Journal of Chemistry CrossRef